Auspex to Present at the Piper Jaffray Healthcare Conference


LA JOLLA, Calif., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that Pratik Shah, Ph.D., President and Chief Executive Officer, will present at the Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 9:50 a.m. EST at the New York Palace Hotel in New York City.

A live webcast of the presentation will be available through the investor relations section of Auspex Pharmaceutical's website, www.auspexpharma.com. Following the live webcast, a replay will be available through the same section for 30 days.

About Auspex Pharmaceuticals

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for hyperkinetic movement disorders and other rare diseases. Auspex employs its proprietary technology to create patent-protected, new chemical entities from known, clinically proven pharmacologics. The company's lead product SD-809 is in final stages of development for the treatment of chorea associated with Huntington's disease, a neurodegenerative movement disorder that impacts cognition, behavior and movements. In addition, Auspex is investing in the broad potential of SD-809 for the treatment of other movement disorders, including tardive dyskinesia and tics associated with Tourette syndrome. The company's pipeline also includes SD-560, being developed for fibrotic conditions. For further information, please visit the company's website www.auspexpharma.com.


            

Contact Data